We are thrilled to announce that Recursion has successfully raised an impressive $785 million in its latest funding round, further solidifying our commitment to revolutionize the field of drug discovery through advanced technology and scientific research. At Recursion, we leverage the power of established scientific principles and combine them with cutting-edge artificial intelligence to change how new therapies are designed and developed, while also incorporating a scalable approach from the outset. This substantial capital infusion will enable us to enhance our proprietary platform, which integrates high-throughput biology and machine learning, allowing us to identify potential drug candidates faster than ever before. With this funding, we aim to accelerate our existing projects as well as expand our research into new therapeutic areas, ultimately striving to address some of the most pressing healthcare challenges faced by patients worldwide. As we move forward on this journey, we remain dedicated to transparency and innovation, and we look forward to sharing more insights about our progress and initiatives with our community. This milestone not only reflects the confidence that our investors have in our vision and technological advancements but also underscores the important role that sustained funding plays in our mission to unlock the full potential of biology in addressing unmet medical needs. Thank you for your continued support as we embark on the next phase of our journey.





